Eikon Therapeutics, Inc. Common Stock (EIKN) Stock Price
EIKNStock
$7.42
Market Cap$401.90M
P/E—
PEG Ratio—
Div yield—
Beta1.95
EIKN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-39.97%
Price vs S&P 500 (4W)-14.64%
VGM Score53.88
EIKN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.46 | -$1.63 | -11.54%(-$0.17) | |
| Q1 2026 | -$1.22 | -$2.46 | -101.70%(-$1.24) | |
| Q4 2025 | -$17.75 | -$26.23 | -47.78%(-$8.48) |
EIKN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.92
3.92
3.92
3.92
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
EIKNEikon Therapeutics, Inc. Common Stock | — | — | C | — | — | — | — | $7.42 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics is a late-stage clinical biopharmaceutical company developing novel medicines to address serious unmet medical needs using its proprietary drug discovery platform. The company is advancing five product candidates (EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006) through clinical development.